FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2480457822> ?p ?o ?g. }

• W2480457822 abstract "Abstract Background: Renal dysfunction is a common consequence of MM. Patients can present with varying degrees of renal impairment during the course of their disease. Clinical management of these patients remains a challenge and the role of newer agents like bortezomib is still being defined in them. We have previously reported on the safety and efficacy of bortezomib in MM patients with advanced renal failure requiring dialysis. Here we further evaluate if varying degree of renal dysfunction as determined by the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (NKF K/DOQI), adversely affects the clinical outcome of bortezomib-based therapies. Methods: All MM patients treated with bortezomib or bortezomib-based therapies were evaluable for this analysis. Response to treatment was classified as per EBMT criteria. Renal function stratification was done for all the patients based on NKF K/DOQI guideline stages as per glomerular filteration rate (GFR; ml/min/1.73 m2). Stages 1, 2, 3, 4 and 5 were defined as GFR ≥ 90, 60–89, 30–59, 15–29, and &lt; 15/dialysis, respectively. To study the statistical relationship between pairs of nominal variables, Fisher’s exact test was used. To study the statistical relationship between nominal and ordinal variables, exact Wilcoxon test was used. A 0.05 nominal significance level was used in all testing. Results: Sixty six consecutive patients were evaluable. Amongst these, 32 (48.5%) were females and 34 (51.5%) males with a median age of 59.5 years (range 40–82 years). Fifty five (83%) patients had advanced MM; stage &gt; I as per Durie-Salmon (DS) criteria. Eligible patients had either relapsed/refractory disease (n=33) or were previously untreated (n=33). NKF K/DOQI renal function stages were 1, 2, 3, 4 and 5 in 9 (13.6%), 29 (44%), 22 (33.4%), 3 (4.5%) and 3 (4.5%) patients, respectively. Clinical response observed was complete remission (CR) in 8 (12%), partial remission (PR) in 25 (38%), stable disease (SD) in 27 (41%) and progressive disease (PD) in 6 (9%) patients. There was no significant association between renal function and patient age (p = 0.0808; 95% CI -0.0246, 0.4367), DS stage (p = 0.1722; 95% CI -0.0806, 0.4744), Ig type (p = 0.5288), untreated vs. relapsed/refractory disease (p = 0.1352), or response to treatment (p = 0.5292; 95% CI -0.1601, 0.3114). Conclusions: In this paper we investigated the correlation of NKF K/DOQI renal function stage in myeloma patients with clinical response to bortezomib. We noted that patients treated with bortezomib-based therapies experienced similar clinical benefit irrespective of the NKF K/DOQI renal function stage. These findings further support our previous observation that bortezomib is an effective therapeutic option for MM patients with renal dysfunction. Best Response to Treatment in Each NKF K/DOQI Stage Stage Best Response To Treatment NKF K/DOQI; National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative, PD; Progressive Disease, SD; Stable Disease, PR; Partial Remission, CR; Complete Remission PD SD PR CR Total 1 1 3 4 1 9 2 3 14 10 2 29 3 2 6 9 5 22 4 0 1 2 0 3 5 0 3 0 0 3 Total 6 27 25 8 66" @default.
• W2480457822 created "2016-08-23" @default.
• W2480457822 creator A5006011014 @default.
• W2480457822 creator A5010286156 @default.
• W2480457822 creator A5016601438 @default.
• W2480457822 creator A5019400643 @default.
• W2480457822 creator A5042245087 @default.
• W2480457822 creator A5042347518 @default.
• W2480457822 creator A5044589378 @default.
• W2480457822 date "2007-11-16" @default.
• W2480457822 modified "2023-10-17" @default.
• W2480457822 title "Renal Dysfunction Does Not Affect Clinical Response in Multiple Myeloma (MM) Patients Treated with Bortezomib-Based Regimens." @default.
• W2480457822 doi "https://doi.org/10.1182/blood.v110.11.1477.1477" @default.
• W2480457822 hasPublicationYear "2007" @default.
• W2480457822 type Work @default.
• W2480457822 sameAs 2480457822 @default.
• W2480457822 citedByCount "7" @default.
• W2480457822 countsByYear W24804578222012 @default.
• W2480457822 countsByYear W24804578222013 @default.
• W2480457822 crossrefType "journal-article" @default.
• W2480457822 hasAuthorship W2480457822A5006011014 @default.
• W2480457822 hasAuthorship W2480457822A5010286156 @default.
• W2480457822 hasAuthorship W2480457822A5016601438 @default.
• W2480457822 hasAuthorship W2480457822A5019400643 @default.
• W2480457822 hasAuthorship W2480457822A5042245087 @default.
• W2480457822 hasAuthorship W2480457822A5042347518 @default.
• W2480457822 hasAuthorship W2480457822A5044589378 @default.
• W2480457822 hasConcept C126322002 @default.
• W2480457822 hasConcept C126894567 @default.
• W2480457822 hasConcept C141071460 @default.
• W2480457822 hasConcept C159641895 @default.
• W2480457822 hasConcept C2776364478 @default.
• W2480457822 hasConcept C2777478702 @default.
• W2480457822 hasConcept C2778653478 @default.
• W2480457822 hasConcept C2779978075 @default.
• W2480457822 hasConcept C71924100 @default.
• W2480457822 hasConceptScore W2480457822C126322002 @default.
• W2480457822 hasConceptScore W2480457822C126894567 @default.
• W2480457822 hasConceptScore W2480457822C141071460 @default.
• W2480457822 hasConceptScore W2480457822C159641895 @default.
• W2480457822 hasConceptScore W2480457822C2776364478 @default.
• W2480457822 hasConceptScore W2480457822C2777478702 @default.
• W2480457822 hasConceptScore W2480457822C2778653478 @default.
• W2480457822 hasConceptScore W2480457822C2779978075 @default.
• W2480457822 hasConceptScore W2480457822C71924100 @default.
• W2480457822 hasLocation W24804578221 @default.
• W2480457822 hasOpenAccess W2480457822 @default.
• W2480457822 hasPrimaryLocation W24804578221 @default.
• W2480457822 hasRelatedWork W1633229201 @default.
• W2480457822 hasRelatedWork W1714859988 @default.
• W2480457822 hasRelatedWork W1970866382 @default.
• W2480457822 hasRelatedWork W1997737526 @default.
• W2480457822 hasRelatedWork W2095328443 @default.
• W2480457822 hasRelatedWork W2105019708 @default.
• W2480457822 hasRelatedWork W2119822303 @default.
• W2480457822 hasRelatedWork W2124543160 @default.
• W2480457822 hasRelatedWork W2914967798 @default.
• W2480457822 hasRelatedWork W3032049302 @default.
• W2480457822 isParatext "false" @default.
• W2480457822 isRetracted "false" @default.
• W2480457822 magId "2480457822" @default.
• W2480457822 workType "article" @default.